Abstract: This invention provides a host-vector complementation system, which permits selection of vector-carrying host cells, without requiring an antibiotic resistance gene. In some embodiments, this system utilizes a host which is guaB deficient and vectors that carry and express the guaB gene. The invention also discloses methods of making and using the system.
Type:
Application
Filed:
April 21, 2008
Publication date:
August 19, 2010
Applicant:
Veritas Bio LLC
Inventors:
Gary Gates, Chandrasekhar Satishchandran
Abstract: Disclosed herein are compositions useful for identification of potential therapeutic agents for the treatment of a disorder associated with RAS deregulation or dysregulation. The compositions may be a yeast cell having one or more mutations in an IRA gene or an ERG gene. Also disclosed are methods of using these compositions.
Type:
Application
Filed:
February 15, 2010
Publication date:
August 19, 2010
Inventors:
YOLANDA SANCHEZ, NANCY RATNER, MATTHEW DUNCAN WOOD
Abstract: A fluid containing cells and free genetic material is acoustically coupled to a propulsion surface of a diaphragm. A blast-receiving surface of the diaphragm is acoustically coupled to an explosion chamber in which an explosive material is disposed. An ignition system ignites the explosive material in the explosion chamber to create a blast wave. The diaphragm transfers momentum from the blast wave to the fluid containing cells and free genetic material sufficient to cause the cells to take up the free genetic material.
Abstract: An object of the present invention is to provide a transformation system for Labyrinthulomycota that allows the elucidation of biosynthetic mechanisms of lipids such as PUFA and carotenoids as well as for the construction of a high production system and the design and development of novel functional lipid molecules by the control of the mechanisms. The present invention provides a vector for the transformation of Labyrinthulomycota with a transgene, which comprises at least (1) a nucleotide sequence which is homologous to a part of chromosomal DNA of Labyrinthulomycota and is capable of homologous recombination with the chromosomal DNA, (2) a selection marker gene having a promoter sequence located upstream and a terminator sequence located downstream, and (3) a cloning site for transgene insertion having a promoter sequence located upstream and a terminator sequence located downstream.
Type:
Grant
Filed:
April 28, 2006
Date of Patent:
July 20, 2010
Assignees:
Fujifilm Corporation, Hiroshima University
Abstract: The present invention relates to process for increased yield of the amino acid arginine from bacterial cultures by employing strains that have been genetically manipulated for both increased arginine biosynthesis and increased level of the Escherichia coli protein YggA or a protein that is substantially similar to Escherichia coli YggA. Two strains of this invention have been deposited at MTCC, Chandigarh. The strains are GJ4894/pHYD952 (MTCC 5127) and GJ4536/pHYD953 (MTCC 5128).
Type:
Grant
Filed:
December 20, 2004
Date of Patent:
July 6, 2010
Assignee:
Centre for DNA Fingerprinting and Diagnostics
Inventors:
Gowrishankar Jayaraman, Madhusudan R. Nandineni
Abstract: Improvements in strain engineering technology are needed to insure the economic feasibility of future engineered recombinant organisms for industrial biotechnology. Disclosed herein are rapid, efficient methods (Genome Mass Transfer) that facilitate introduction of new selectable traits into a target microbial host. In one preferred embodiment, methods for high efficiency electroporation mediated transfer of donor DNA into a recipient microbial cell are disclosed.
Abstract: The invention relates to coryneform bacteria which have, in addition to at least one copy, present at the natural site (locus), of an open reading frame (ORF), gene or allele which codes for the synthesis of a protein or an RNA, in each case a second, optionally third or fourth copy of this open reading frame (ORF), gene or allele at in each case a second, optionally third or fourth site in a form integrated into the chromosome and processes for the preparation of chemical compounds by fermentation of these bacteria.
Type:
Application
Filed:
September 23, 2009
Publication date:
June 24, 2010
Applicant:
EVONIK DEGUSSA GMBH
Inventors:
BRIGITTE BATHE, CAROLINE KREUTZER, BETTINA MOCKEL, GEORG THIERBACH
Abstract: A recombinant operon comprising a gene assembly wherein there are at least two structural genes coding for at least two major subunits of colonization factor antigens (CFs) associated with enterotoxigenic Escherichia coli bacteria (ETEC), is disclosed. Further disclosed is a host cell, such as an Escherichia coli cell, genetically engineered to comprise such a recombinant operon, wherein said operon is located on an episomal element, such as a plasmid, or integrated in the chromosome of said host cell. Also disclosed is a method of producing a host cell capable of expressing from said operon at least two major subunits of colonization factor antigens (CFs) associated with enterotoxigenic Escherichia coli bacteria (ETEC). In addition, a vaccine composition against diarrhea comprising at least one such host cell together with pharmaceutically acceptable excipients, buffers, and/or diluents is disclosed. Finally is disclosed the use of said operon in the production of such a vaccine.
Type:
Application
Filed:
July 1, 2008
Publication date:
June 3, 2010
Applicant:
Crucell Sweden AB
Inventors:
Michael Lebens, Ann-Mari Svennerholm, Joshua Tobias
Abstract: Methods and compositions are provided for producing fuel utilizing various strains of Clostridium phytofermentans with reduced sporulation activity. In some embodiments, the activity of a gene associated with sporulation is reduced. In some embodiments, a fuel producing strain of C. phytofermentans with reduced sporulation activity is provided.
Type:
Application
Filed:
June 11, 2009
Publication date:
April 29, 2010
Inventors:
Jeffrey Blanchard, Susan Leschine, Elsa Petit, John Fabel
Abstract: A modified Family 11 xylanase enzyme comprising a sequence that introduces a functional consensus glycosylation site is provided. Non-limiting examples of introduced glycosylation sites include mutation of the amino acid at position 34, 131, 180, 182, or a combination thereof, to an asparagine. The indicated amino acid position in the Family 11 xylanase is determined from sequence alignment of the xylanase of interest with that of a Trichoderma reesei xylanase II amino acid sequence. The introduced consensus glycosylation site facilitates increased expression efficiency of the modified xylanase when compared to the expression efficiency of a corresponding xylanase from which the modified xylanase was derived, using similar host strains and growth conditions.
Type:
Grant
Filed:
November 7, 2008
Date of Patent:
April 6, 2010
Assignee:
Iogen Bio-Products Corporation
Inventors:
Theresa C. White, Genevieve R. Giroux, Katie E. A. Wallace
Abstract: Methods for producing membrane-spanning polypeptides in high yields, with native conformation, and/or in soluble form include solubilizing in non-ionic or zwitterionic detergents, as well as use of promoters and expression vectors for expressing high yields of membrane-spanning polypeptides in bacterial cells. Mutated promoters provide tight control of membrane-spanning polypeptides in bacterial cell hosts.
Type:
Grant
Filed:
December 22, 2005
Date of Patent:
April 6, 2010
Assignee:
Genentech, Inc.
Inventors:
James A. Ernst, Daniel Yansura, Hok Seon Kim
Abstract: The present invention relates to methods and compositions for engineering Clostridia species. In particular, embodiments of the present invention relate to the expression of recombinant resolvase proteins in Clostridia species.
Type:
Application
Filed:
May 8, 2009
Publication date:
March 25, 2010
Applicant:
NORTHWESTERN UNIVERSITY
Inventors:
Bryan P. Tracy, Eleftherios T. Papoutsakis
Abstract: The present invention is directed to methods for producing and selecting novel mutant strains of B. fragilis that constitutively express a particular capsular polysaccharide or only selected capsular polysaccharides; compositions directed to the novel mutant strains of B. fragilis that constitutively express a particular capsular polysaccharide or only selected capsular polysaccharides; improved methods for purification of individual capsular polysaccharides; and compositions directed to novel res02 and inv19 genes and their gene products. Significantly, the present invention provides methods and compositions for overexpressing and purifying immunomodulatory capsular polysaccharide A (PSA) in high yield.
Type:
Grant
Filed:
January 17, 2007
Date of Patent:
March 16, 2010
Assignee:
The Brigham and Women's Hospital, Inc.
Inventors:
Laurie E. Comstock, Katja G. Weinacht, Michael J. Coyne, Dennis L. Kasper, Arthur O. Tzianabos
Abstract: Lambda phages that can be used to introduce recombineering functions into host cells are disclosed. Also disclosed are plasmids that can be used to confer recombineering functions to a variety of strains of E. coli and to other bacteria, including Salmonella, Pseudomonas, Cyanobacteria, Spirochaetes. These plasmids and phages can be isolated in vitro and can be used to transform bacterial cells, such as gram negative bacteria.
Type:
Grant
Filed:
May 20, 2005
Date of Patent:
March 9, 2010
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Donald L. Court, Simanti Datta, Nina Costantino
Abstract: A method of producing transformation competent bacteria, comprising the steps of: (i) transforming a bacteria that is not naturally transformation competent with a plasmid, wherein said plasmid comprises a comX gene sequence encoding a ComX protein or functional part or derivative or variant thereof under the regulatory control of a promoter which is inducible by a transcription initiator, (ii) contacting said transformed bacteria with said transcription initiator to initiate transcription of said comX gene sequence is provided. Also provided are plasmids, transformed bacteria, transformation competent bacteria, mutant bacteria and food products comprising said mutant bacteria.
Abstract: Recombinant Mycobacterium strains with improved vaccinal properties for use as vaccinating agents are provided. The parent strains of the recombinant Mycobacterium strains are selected for their potent immunogenicity. The Mycobacterium strains do not display antibiotic resistance, and do not exhibit horizontal transfer to gram-negative bacteria.
Type:
Grant
Filed:
November 29, 2005
Date of Patent:
December 1, 2009
Assignee:
Aeras Global TB Vaccine Foundation
Inventors:
Ronggai Sun, David Michael Hone, Jerald C. Sadoff
Abstract: The invention relates to novel polyenes having formula (I), wherein: R1 represents alkyl C1-C3; and R2 represents a functional group selected from CH3— or CONH2— (methyl- or primary amide-). The aforementioned polyenes have a biocide action on organisms comprising cell membranes that contain ergosterol, e.g., fungi or parasites. Said compounds can be obtained using a method that consists in cultivating a producing micro-organism under conditions that enable the production thereof. In addition, the invention also relates to a mechanism for the in vitro production of amidated polyenes, consisting in incubating carboxylated polyenes with cell-free extracts (or proteinaceous fractions) of the producers of same in the presence of ATP/Mg++ and an amide- group donor compound (preferably glutamine).
Type:
Application
Filed:
March 23, 2006
Publication date:
September 3, 2009
Inventors:
Francisco Malpartida Romero, Elena Maria Seco Martin, Trinidad Cuesta Velasco
Abstract: The invention relates to an expression vector of a gene coding for an antigenic protein of Leishmania promastigote, characterised in that it comprises a PSA gene insert in opposite orientation. The invention can be applied to the development of mutants under-expressing, or no longer expressing, genes coding for an antigenic protein of Leishmania promastigote, and to the therapeutic and/or vaccine-oriented uses thereof.
Type:
Application
Filed:
February 10, 2006
Publication date:
August 27, 2009
Applicant:
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)
Inventors:
Jean-Loup Lemesre, Philippe Holzmuller, Rachel Bras-Goncalves
Abstract: An object of the present invention is to provide a method of efficiently constructing a gene delivery carrier having a favorable activity and expression efficiency of a protein expressed by a gene introduced by transformation. Moreover, an object of the present invention is to provide a pharmaceutical composition comprising a gene delivery carrier constructed by the construction method and a therapeutic agent for solid tumor comprising the resistant bacterium.
Abstract: Provided herein are improved copy number plasmids, particularly those plasmids capable of replication in a bacterial cell. The improved copy number plasmid contain a deletion, insertion, or substitution in the replication control region, particularly a Pseudomonas-specific replication control region, that results in an increase in plasmid copy number in comparison to a control plasmid. Also provided are host cells containing the improved copy number plasmids, as well as methods of using the improved copy number plasmids for the recombinant production of a protein of interest. Further provided are methods for generating plasmids with improved copy number. The methods disclosed herein involve the reiterative selection of improved copy number plasmids by the growth and selection of plasmids capable of growth under increasing selective pressure, wherein the selective pressure is applied utilizing a selection agent to which the control plasmid confers resistance.
Abstract: This invention provides a modified vaccinia topoisomerase enzyme containing an affinity tag which is capable of facilitating purification of protein-DNA complexes away from unbound DNA. This invention further provides a modified sequence specific topoisomerase enzyme. This invention provides a method of ligating duplex DNAs, a method of molecular cloning of DNA, a method of synthesizing polynucleotides, and a method of gene targeting. Lastly, this invention provides a recombinant DNA molecule composed of segments of DNA which have been joined ex vivo by the use of a sequence specific topoisomerase and which has the capacity to transform a suitable host cell comprising a DNA sequence encoding polypeptide activity.
Type:
Grant
Filed:
March 3, 2006
Date of Patent:
June 23, 2009
Assignee:
Sloan-Kettering Institute for Cancer Research
Abstract: The present invention provides a nucleic acid encoding nicotinamide phosphoribosyltransferase (NadV) from a V-factor independent bacterium and provides methods for using the gene as a selection marker for constructing recombinant bacteria from V-factor dependent bacteria. The method is an improvement over methods which rely on nucleic acids which confer antibiotic resistance for constructing recombinant bacteria. Methods for constructing attenuated recombinant Actinobacillus pleuropneumoniae using the selection method of the present invention are also provided.
Type:
Application
Filed:
April 4, 2008
Publication date:
April 16, 2009
Applicant:
Board of Trustees of Michigan State University
Inventors:
Martha H. Mulks, Paul R. Martin, Robin J. Shea
Abstract: The present invention is directed to isolated nucleic acid molecules that encode LIM mineralization protein, or LMP. The invention further provides vectors comprising splice variants of nucleotide sequences that encode LMP, as well as host cells comprising those vectors. Moreover, the present invention relates to methods of inducing bone formation by transfecting osteogenic precursor cells with an isolated nucleic acid molecule comprising a nucleotide sequence encoding splice variants of LIM mineralization protein. The transfection may occur ex vivo or in vivo by direct injection of virus or naked plasmid DNA. In a particular embodiment, the invention provides a method of fusing a spine by transfecting osteogenic precursor cells with an isolated nucleic acid molecule having a nucleotide sequence encoding LIM mineralization protein, admixing the transfected osteogenic precursor cells with a matrix and contacting the matrix with the spine.
Abstract: A gene isolated from a microorganism selected from the group consisting of Pantoea bacteria, Erwinia bacteria, and Enterobacter bacteria, and encoding a Rep protein or a homologue thereof is described. A plasmid containing the gene which is autonomously replicable in Enterobacteriaceae bacteria is also described. A Enterobacteriaceae microorganism containing the plasmid is also described.
Abstract: The present invention provides an expression vector comprising genes encoding OmpF of E. coli and a desired protein, E.coli transformed with the expression vector, and a method for extracellular production of desired proteins by employing the same. The recombinant expression vector of the invention comprises an ampicillin-resistance gene, the OmpF promoter and the OmpF gene. In accordance with the invention, a desired protein can be produced extracellularly by a simpler method than conventional methods such that: secretory production of OmpF fusion protein begins simultaneously with growth of the cells through constitutive expression employing an OmpF promoter, and as the concentration of cells increases, the amount of secretory production of the protein also increases continuously. Therefore, desired proteins can be produced in large quantities by a high concentration culture of cells.
Type:
Grant
Filed:
June 19, 2003
Date of Patent:
February 17, 2009
Assignee:
Korea Advanced Institute of Science and Technology
Abstract: The present invention discloses functional plasmids in bacteria of the Acidithiobacillus genus, such as the Acidithiobacillus ferrooxidans, Acidithiobacillus thiooxidans and Acidithiobacillus caldus species. And a method to successfully transform bacteria of the Acidithiobacillus genus, such as the Acidithiobacillus ferrooxidans, Acidithiobacillus thiooxidans and Acidithiobacillus caldus species, with these plasmids.
Type:
Application
Filed:
July 16, 2008
Publication date:
February 5, 2009
Applicant:
BIOSIGMA S.A.
Inventors:
Pilar A. Parada Valdecantos, Patricio Ernesto Martinez Bellange
Abstract: The invention relates to methods for the fermentative production of sulfur-containing fine chemicals, in particular L-methionine, by using bacteria which express a nucleotide sequence coding for a methionine synthase (metH) gene.
Type:
Grant
Filed:
April 16, 2003
Date of Patent:
February 3, 2009
Assignee:
Evonik Degussa GmbH
Inventors:
Burkhard Kröger, Oskar Zelder, Corinna Klopprogge, Hartwig Schröder, Stefan Häfner
Abstract: The present invention provides a simple method for splitting and loss of a chromosome in yeast. The method for modifying a chromosome in yeast includes preparing a linear chromosome splitting vector (1) having a target sequence (a), a marker gene sequence and (C4A2)n sequence in this order; preparing a linear chromosome splitting vector (2) having a target sequence (b), a centromere sequence of a yeast chromosome and (C4A2)n sequence in this order; and introducing the chromosome splitting vectors (1) and (2) into yeast. Herein, n is each independently an integer of 6 to 10. Although this chromosome splitting vector has a repetitive sequence of 5?-CCCCAA-3?, it can be amplified specifically with PCR, so that a chromosome splitting vector can be prepared significantly simply and easily, compared with the conventional DNA splitting method.
Abstract: Site-specific Listeria integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a polypeptide coding sequence, e.g., for a heterologous antigen. The subject vectors and methods find use in a variety of different applications, including the study of Listeria species and the preparation of Listeria vaccines.
Type:
Grant
Filed:
April 30, 2002
Date of Patent:
September 16, 2008
Assignee:
The Regents of the University of California
Inventors:
Daniel A. Portnoy, Richard Calendar, Peter M. Lauer
Abstract: The invention relates to methods for cloning Human Immunodeficiency Virus (HIV) genes, in particular HIV envelope genes. The invention also relates to cloning strategies for mapping resistance determinants for HIV genes, in particular HIV envelope genes.
Abstract: A plasmid has been isolated from Rhodococcus erythropolis strain AN12 comprising a unique replication protein. The replication protein may be used in a variety of cloning and expression vectors and particularly in shuttle vectors for the expression of heterologous genes in Rhodococcus sp.
Type:
Grant
Filed:
March 1, 2005
Date of Patent:
August 26, 2008
Assignee:
E.I. du Pont de Nemours and Company
Inventors:
Michael G. Bramucci, Qiong Cheng, Kristy N. Kostichka, Jean-Francois Tomb
Abstract: A whole cell catalyst is described comprising a hydantoinase, a racemase and a carbamoylase. Thus this catalyst is able to degrade hydantoins directly into the amino acids. Additionally, a process for the production of this catalysts and for the production of amino acids is claimed.
Type:
Grant
Filed:
January 2, 2003
Date of Patent:
July 1, 2008
Assignees:
University of Stuttgart, Degussa AG
Inventors:
Joseph Altenbuchner, Ralf Mattes, Christoph Syldatk, Anja Wiese, Burkard Wilms, Andreas Bommarius, Wilhelm Tischer
Abstract: A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the treatment of hypersecretion of mucus, which inhibits mucus secretion by inhibiting mucus secretion by mucus secreting cells, and/or inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.
Type:
Application
Filed:
June 6, 2007
Publication date:
June 26, 2008
Inventors:
Conrad Padraig Quinn, Keith Alan Foster, John Chaddock
Abstract: This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and re-arrangements, in the place of the genome are obtained.
Type:
Grant
Filed:
August 2, 2000
Date of Patent:
April 22, 2008
Assignee:
Wyeth
Inventors:
David K. Clarke, J. Erik Johnson, Mohinderjit S. Sidhu, Stephen A. Udem
Abstract: Novel food-grade cloning vectors comprising a nonsense mutation suppressor-encoding gene, which vector, when it is present in a lactic acid bacterial strain, permits such a strain to have an industrially appropriate growth rate and metabolic activity. The cloning vectors are useful when present in lactic acid bacteria used as starter cultures in the preparation of food or feed products, or a dairy flavor.
Type:
Grant
Filed:
April 14, 1999
Date of Patent:
April 15, 2008
Assignee:
Chr. Hansen A/S
Inventors:
Kim Sorensen, Rasmus Larsen, Eric Johansen
Abstract: Methods are provided for manipulating nucleic acid to produce gene fusions, to delete or clone a portion of a chromosome, or to insert a sequence into a chromosome. The methods employ sequential transposition processes using two or more pairs of inverted repeat transposase-interacting sequences on a transposable polynucleotide wherein each pair of transposase-interacting sequences interacts with a distinct transposase enzyme.
Type:
Grant
Filed:
March 7, 2006
Date of Patent:
March 4, 2008
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Igor Yu Goryshin, Todd A Naumann, William S Reznikoff
Abstract: The present invention relates to mutants cells comprising a marker-free modification of a gene, and methods for obtaining and using such mutant cells.
Type:
Grant
Filed:
March 31, 2005
Date of Patent:
February 19, 2008
Assignee:
Novozymes, Inc.
Inventors:
John C. Royer, Lynne M. Christanson, Gregory A. Gambetta, Howard Brody, Suzanne M. Otani, Wendy T. Yoder
Abstract: The invention relates to nucleic acid constructions, characterized in that they comprise nucleic acids which are isolated in the sense position and which are capable of coding for an immunogenic protein of promastigotes or amastigotes of Leishmania, said nucleic acids responding to one of the sequences SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5 et SEQ ID No. 11 and coding for a protein respectively exhibiting a sequence SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10 et SEQ ID No. 12. The invention can be used for over-expression of the genes of Leishmania coding for an excretion/secretion antigen.
Type:
Application
Filed:
November 19, 2004
Publication date:
January 31, 2008
Inventors:
Jean-Loup Lemesre, Mireille Cavaleyra, Denis Sereno, Philippe Holzmuller
Abstract: A novel protein which has an activity to transport hydantoin compounds is described, as well as a recombinant expressing this transporter protein. From Microbacterium liquefaciens strain AJ3912, a novel gene was discovered to encode a protein which is able to transport hydantoin compounds. A recombinant with an excellent ability to uptake hydantoin compounds is obtained by introducing and expressing the novel gene, called mhp, using gene recombination techniques.
Type:
Grant
Filed:
March 8, 2006
Date of Patent:
January 22, 2008
Assignee:
Ajinomoto Co., Inc.
Inventors:
Shunichi Suzuki, Kenzo Yokozeki, Peter Henderson
Abstract: The invention provides novel yeast promoters useful for controlling the expression of homologous and heterologous nucleic acid molecules in yeast cells. The yeast promoters are induced by a fermentable carbon source, such as glucose, or a non-fermentable carbon source, such as ethanol, or both. Therefore, expression of nucleic acid molecules encoding a polypeptide under the control of the novel yeast promoters may be regulated by varying the level of a fermentable carbon source, or a non-fermentable carbon source, or both.
Abstract: Nucleic acids and polypeptides involved in regulation of membrane permeability in bacteria are disclosed. Also disclosed are methods of increasing sensitivity to antibiotics in multi-drug resistant bacteria by increasing expression of PprA or PprB proteins in bacterial cells, and methods for identifying compounds that modulate PprA/PprB expression.
Type:
Grant
Filed:
April 29, 2003
Date of Patent:
September 18, 2007
Assignee:
University of Florida Research Foundation, Inc.
Abstract: The present invention discloses the use of a mutant Leishmania as a suicidal vaccine wherein the mutant Leishmania is responsive to external signals to become porphyric and commit suicidal cytolysis. The mutant can be selected from natural Leishmania species or constructed by genetic engineering.
Type:
Grant
Filed:
March 28, 2005
Date of Patent:
July 3, 2007
Assignee:
Rosalind Franklin University of Medicine and Science
Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
Type:
Grant
Filed:
January 6, 2006
Date of Patent:
May 22, 2007
Assignee:
Novozymes, Inc.
Inventors:
Kimberly Brown, Paul Harris, Alfredo Lopez De Leon, Sandra Merino
Abstract: Promoters capable of efficiently expressing a gene of interest in plants include (1) either a DNA containing SEQ ID No:1 or SEQ ID No:7, or a biological functional equivalent DNA containing SEQ ID No:1 or SEQ ID No:7 that have modifications in their respective nucleotide sequence provided that each retains more than 90% identity to the nucleotide sequence of any region containing at least 250 bp within SEQ ID No:1 or SEQ ID No:7, respectively. Terminators capable of efficiently expressing a gene of interest in plants include either a DNA containing SEQ ID No:2, or a biological functional equivalent DNA containing a SEQ ID No:2 that has a modified nucleotide sequence provided that it retains more than 90% identity to the nucleotide sequence of any region containing at least 250 bp within SEQ ID No:2.
Abstract: An Actinobacillus succinogenes plasmid vector which provides a means to overexpress proteins in A. succinogenes. The plasmid can be transformed efficiently by electroporation, and replicates in a stable manner in A. succinogenes. The plasmid comprises at least one marker gene, operably linked to a first promoter functional in Actinobacillus succinogenes, an origin of replication functional in Actinobacillus succinogenes, a second promoter isolated from Actinobacillus succinogenes, and a cloning site downstream from the second promoter. Plasmids pLGZ901, pLGZ920, pLGZ921, and pLGZ922 are disclosed. The pckA gene polypeptide sequence and nucleic acid sequence of Actinobacillus succinogenes, including the promoter and ribosome binding site, is disclosed. Furthermore, a method for producing a recombinant Actinobacillus succinogenes is described, including a method of transformation.
Type:
Grant
Filed:
January 25, 2005
Date of Patent:
March 27, 2007
Assignee:
Board of Trustees of Michigan State University
Inventors:
J. Gregory Zeikus, Maris Laivenieks, Claire Vieille, Pil Kim
Abstract: A method of providing papillomavirus like particles which may be used for diagnostic purposes or for incorporation in a vaccine for use in relation to infections causd by papillomavirus. The method includes an initial step of constructing one or more recombinant DNA molecules which each encode papillomavirus L1 protein or a combination of papillomavirus L1 protein and papillomavirus L2 protein followed by a further step of transfecting a suitable host cell with one or more of the recombinant DNA molecules so that virus like particles (VLPs) are produced within the cell after expression of the L1 or combination of L1 and L2 proteins. The VLPs are also claimed per se as well as vaccines incorporating the VLPs.
Abstract: An Actinobacillus succinogenes plasmid vector which provides a means to overexpress proteins in A. succinogenes. The plasmid can be transformed efficiently by electroporation, and replicates in a stable manner in A. succinogenes. The plasmid comprises at least one marker gene, operably linked to a first promoter functional in Actinobacillus succinogenes, an origin of replication functional in Actinobacillus succinogenes, a second promoter isolated from Actinobacillus succinogenes, and a cloning site downstream from the second promoter. Plasmids pLGZ901, pLGZ920, pLGZ921, and pLGZ922 are disclosed. The pckA gene polypeptide sequence and nucleic acid sequence of Actinobacillus succinogenes, including the promoter and ribosome binding site, is disclosed. Furthermore, a method for producing a recombinant Actinobacillus succinogenes is described, including a method of transformation.
Type:
Grant
Filed:
August 5, 2004
Date of Patent:
January 16, 2007
Assignee:
Board of Trustees of Michigan State University
Inventors:
J. Gregory Zeikus, Maris Laivenieks, Claire Vieille, Pil Kim
Abstract: Expression vectors and yeast cells that contain a heterologous G protein-coupled receptor gene and a gene mutation that causes increased sensitivity to receptor activation or a gene mutation that permits transcriptional activation of pheromone-responsive genes without cell cycle arrest. Methods of making the yeast cells.
Type:
Grant
Filed:
November 25, 2002
Date of Patent:
December 12, 2006
Assignee:
BASF Aktiengesellschaft
Inventors:
Mark Henry Pausch, Bradley Alton Ozenberger, John Richard Hadcock, Laura Alicia Price, Eileen Marie Kajkowski, Donald Richard Kirsch, Deborah Tardy Chaleff
Abstract: A process for the production of an L-amino acid wherein coryneform bacteria (e.g. Coryneform glutamicum) in which expression of the mqo gene coding for malate quinone oxidoreductase is attenuated are fermented to produce a desired amino acid, and the amino acid is concentrated in the medium or cells and isolated. Optionally, further genes in the biosynthetic pathway of the desired amino acid are enhanced, and/or metabolic pathways that reduce formation of the amino acid are suppressed.
Type:
Grant
Filed:
November 2, 2005
Date of Patent:
December 5, 2006
Assignee:
Degussa AG
Inventors:
Mike Farwick, Brigitte Bathe, Thomas Hermann, Achim Marx, Walter Pfefferle